KOMZIFTI's Early Commercial Growth
Kura Oncology reports Q2 $68.3M loss amid rising KOMZIFTI product sales and R&D investment
Key Points
Q2 2026 revenue mix shows product revenue of $9.122 million and collaboration revenue of $11.752 million, totaling $20.874 million for the quarter (with a first-half total of $39.139 million).
Six-month spend indicates R&D expenses of $61.891 million and SG&A expenses of $31.750 million, with share-based compensation totaling $16.625 million for the six-month period.
Cash burn remains substantial, with net cash used in operating activities totaling $148.403 million for the six months ended June 30, 2026 (up from $100.704 million in the prior-year period).
Early commercial activity includes more than 250 total prescriptions (TRx) in 2Q 2026, signaling ongoing uptake of KOMZIFTI in its initial market window.
Insider and institutional trading activity shows 108 institutions adding KURA shares in the latest period, with notable moves such as Deep Track Capital purchasing 2,643,542 shares and BlackRock increasing its stake by 871,702 shares; insiders reported four sales and no purchases in the period.
Kura Oncology posted a net loss of $68.3 million on $20.9 million in revenue for Q2 2026, as the company ramps up its first commercial drug, KOMZIFTI (ziftomenib), a treatment for a rare and hard-to-treat form of blood cancer called acute myeloid leukemia (AML). Kalkine Media reported that the first-half net loss reached $141.7 million, reflecting heavy spending as the company builds out its pipeline and sales operation.
Despite the large loss, the quarter showed early commercial momentum. Product revenue jumped 57% from the prior quarter, driven by roughly 115 new patient starts and more than 250 total prescriptions written during Q2, according to Yahoo Finance.
KOMZIFTI Gains Ground in a Rare Cancer Market
KOMZIFTI targets patients with NPM1-mutated AML who have relapsed or stopped responding to other treatments. This is a small but underserved patient population. Yahoo Finance noted that the drug captured a majority of new patient starts in its niche during Q2, a key early sign that doctors are adopting it.
Product revenue came in at $9.1 million for the quarter. An additional $11.8 million came from collaboration deals, bringing the total to $20.9 million. GuruFocus called this a critical period for the company as it works to establish a foothold in the AML market.
Earnings Beat Estimates Despite Revenue Miss
Kura's loss of $0.77 per share beat the Zacks consensus estimate of $1.89 per share, according to Yahoo Finance. That is a wide gap, suggesting analysts had expected a much steeper loss. Revenue of $20.87 million, however, came in below expectations.
ScanX Trade noted the net loss of $68.3 million beat the analyst consensus of $21.42 million by about 2.55%. The EPS beat is largely tied to non-cash items like stock-based compensation, which totaled $16.6 million for the first half of the year.
Heavy Spending Drives a $148 Million Cash Burn
Kura is spending aggressively to build out its drug pipeline and commercial team. R&D expenses hit $61.9 million in the first half of 2026. SG&A — the cost of running sales and operations — added another $31.8 million, according to Kalkine Media.
Net cash used in operations reached $148.4 million for the six months ended June 30, 2026. That is up sharply from $100.7 million in the same period a year earlier. The high burn rate signals that Kura is investing heavily now, betting on long-term growth from KOMZIFTI and its broader pipeline.
Institutions Load Up on KURA Shares Despite Insider Sales
Big investors appear to be betting on Kura's future. A total of 108 institutions added KURA shares in the latest period. Deep Track Capital bought 2,643,542 shares. BlackRock increased its stake by 871,702 shares. These are meaningful votes of confidence from major players.
On the insider side, the picture was more cautious. Company insiders reported four share sales and zero purchases during the period. That gap between institutional buying and insider selling is worth watching as KOMZIFTI moves deeper into its commercial launch phase.
Sentiment
Mostly PositivePublishers
11
Articles
16
Reach
27
